The trial is being carried out under an approval from the Israeli Ministry of Health and will be for 15 patients. Each patient will receive between 6 and 12 injections of the therapeutic vaccine ImMucin over a 3-6 month period and there will be follow-up for an additional 6 months. The study will be looking at safety and a number of biomarkers specific to the disease.

“We are very excited about the initiation of the clinical trial using ImMucin. Therapeutic vaccines are one of the most promising classes of immunotherapeutic in the fight against cancer and ImMucin has shown great promise in pre-clinical studies” said Lior Camon, Vaxil’s CEO.

About Vaxil
Vaxil BioTherapeutics, based in Israel, is a pioneer in the development of novel T-cell synthetic vaccines for both therapeutic and prophylactic use. Using a proprietary technology VaxHit™ the company has identified a large number of vaccine candidates in the fields of cancer and infectious diseases. As well as ImMucin, the company is also developing MTBuVax, a new multi-epitope vaccine for mycobacterium Tuberculosis.

“Vaxil has an innovative approach for identifying cancer antigens that get presented more efficiently by the MHC molecules. Vaxil's long peptides are good candidates for formulation in our DepoVax platform making this an interesting research partnership” remarked Dr. Marc Mansour, vice president of R&D at Immunovaccine.

“In preclinical studies, the DepoVax™ delivery platform has a demonstrated ability to enhance vaccines, generating a prolonged immune response. We believe that this could fit well with our products and we look forward to making strong advances together in developing the next generation of cancer therapeutics,” said Dr. Lior Carmon, founder and CEO of Vaxil BioTherapeutics.

Vaxil BioTherapeutics, based in Israel, is a pioneer in the development of novel T-cell synthetic vaccines for both therapeutic and prophylactic use. Using a proprietary technology VaxHit™ the company has identified a large number of vaccine candidates in the fields of cancer and infectious diseases. The company’s lead product – ImMucin™, an anti-MUC1 therapeutic cancer vaccine has received regulatory permission to start Phase I/II clinical trials in Multiple Myeloma patients, due to commence in 2010. vaxilbio.com

Immunovaccine Inc. (TSX-V:IMV), based in Canada, is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery technology. The company’s lead product DPX-0907, a therapeutic cancer vaccine is in a Phase 1 clinical trial in the US. Immunovaccine continues to strengthen its vaccine pipeline, through licensing and strategic partnerships, to develop therapeutic cancer and infectious disease vaccines.

Dr. Carmon will be presenting an update on Vaxil's mTbuVax™ vaccine for  the patohgenic bactria tuberculosis. Tuberculosis is a growing problem not just in the third world but also in western countries and in Israel. Incidence rates in the developed world are rising rapidly due to the development of drug resistant strains of the disease, the ineffectiveness of current vaccines, global travel, the rise of TB as a co-factor with HIV infection. The global market for TB vaccines is estimated at around $1bn a year

About Vaxil
Vaxil BioTherapeutics is a pioneer in the development of novel T cell synthetic vaccines for both therapeutic and prophylactic use. Using a proprietary technology VaxHit™ it has identified a large number of vaccine candidates in the fields of cancer and infectious diseases. The company’s lead product – ImMucin™, an anti-MUC1 therapeutic cancer vaccine has received regulatory permission to start Phase I/II clinical trials in Multiple Myeloma patients. Vaxil is also developing a new vaccine for the treatment of tuberculosis, mTBuVax which is in pre-clinical studies. Vaxil was established in 2007 by an experienced management team backed up by leading figures in the academic world. The company is based in Nes-Ziona, Israel.  

The conference will take place on May 14-19, 2010 at New Orleans, LA. Vaxil will present the latest results of it’s work on a ground breaking vaccine for the treatment and prevention of Tuberculosis. For more information pls see Kovjazin et al., Am. J. Respir. Crit. Care Med. 2010; 181:A1383.  Tuberculosis is a growing problem not just in the third world but also in western countries and in Israel. Incidence rates in the developed world are rising rapidly due to the development of drug resistant strains of the disease, the ineffectiveness of current vaccines, global travel, the rise of TB as a co-factor with HIV infection. The global market for TB vaccines is estimated at around $1bn a year.

About Vaxil

Vaxil BioTherapeutics is a pioneer in the development of novel T cell synthetic vaccines for both therapeutic and prophylactic use. Using a proprietary technology VaxHit™ it has identified a large number of vaccine candidates in the fields of cancer and infectious diseases. The company’s lead product – ImMucin™, an anti-MUC1 therapeutic cancer vaccine has received regulatory permission to start Phase I/II clinical trials in Multiple Myeloma patients. Vaxil was established in 2007 by an experienced management team backed up by leading figures in the academic world. The company is based in Nes-Ziona, Israel.

The conference will take place on February 4th 2010 at the faculty of medicine, Technion Haifa. Vaxil will present the company’s work on a ground breaking vaccine for the treatment and prevention of Tuberculosis. Tuberculosis is a growing problem not just in the third world but also in western countries and in Israel. Incidence rates in the developed world are rising rapidly due to the development of drug resistant strains of the disease, the ineffectiveness of current vaccines, global travel, the rise of TB as a co-factor with HIV infection. The global market for TB vaccines is estimated at around $1bn a year.

About Vaxil

Vaxil BioTherapeutics is a pioneer in the development of novel T cell synthetic vaccines for both therapeutic and prophylactic use. Using a proprietary technology VaxHit™ it has identified a large number of vaccine candidates in the fields of cancer and infectious diseases. The company’s lead product – ImMucin™, an anti-MUC1 therapeutic cancer vaccine has received regulatory permission to start Phase I/II clinical trials in Multiple Myeloma patients. Vaxil was established in 2007 by an experienced management team backed up by leading figures in the academic world. The company is based in Nes-Ziona, Israel.